| ATP-binding cassette transporter A1 (ABCA1) belongs to the ABC transporter superfamily and functions as an integral membrane protein regulating cellular cholesterol and phospholipid homeostasis through ATP-dependent substrate translocation across plasma membranes. ABCA1 contains two transmembrane domain bundles, each comprising six membrane-spanning helices, two cytoplasmic nucleotide-binding domains responsible for ATP hydrolysis that powers transport, and a C-terminal PDZ domain mediating protein-protein interactions alongside a VFVNFA motif essential for lipid efflux activity. The protein mediates cholesterol and phospholipid efflux to lipid-poor apolipoproteins, predominantly apolipoprotein A-I (apoA-I) and apolipoprotein E (apoE), through a multi-step process initiating with the formation of specialized cell surface lipid domains enriched in cholesterol and phospholipids. Apolipoprotein binding to ABCA1 triggers conformational changes activating multiple downstream signaling cascades, including Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3), protein kinase A (PKA), Rho family GTPase CDC42, and protein kinase C (PKC), positioning ABCA1 as both a lipid transporter and a signaling receptor. PKA and CDC42 activation directly regulates ABCA1-mediated lipid efflux by modulating transporter conformation and membrane dynamics, while PKC phosphorylation stabilizes ABCA1 protein by reducing its degradation, and JAK2/STAT3 signaling controls both lipid efflux efficiency and anti-inflammatory responses. The interaction between apoA-I and ABCA1 solubilizes membrane cholesterol and phospholipids, generating nascent high-density lipoprotein (nHDL) particles that serve as acceptors for additional free cholesterol from peripheral cells, with subsequent lecithin:cholesterol acyltransferase-mediated esterification converting nHDL to mature HDL that transports cholesterol to the liver for biliary secretion and fecal excretion, constituting the reverse cholesterol transport pathway. ABCA1 executes anti-inflammatory functions independent of cholesterol efflux by modifying lipid raft composition within cell membranes, which alters Toll-like receptor 4 (TLR4) signaling and reduces expression of inflammatory cytokines and chemokines in macrophages, linking sterol efflux activities to immunomodulatory effects. The transporter exhibits ubiquitous tissue expression with particularly high abundance in liver, small intestine, and adipose tissue where lipid turnover predominates, and regulatory control occurs through transcriptional mechanisms involving liver X receptor (LXR) activation by oxysterols and through post-translational modifications, including calpain-mediated proteolysis that degrades ABCA1 protein. ABCA1 regulates membrane cholesterol content in skeletal muscle transverse tubules, modulating insulin-dependent GLUT4 translocation and glucose uptake, with reduced ABCA1 expression causing cholesterol accumulation that impairs insulin signaling through decreased Akt phosphorylation at Ser473. Loss-of-function mutations in ABCA1 cause Tangier disease, an autosomal recessive disorder characterized by severely reduced high-density lipoprotein cholesterol levels, cholesteryl ester accumulation in tissue macrophages, producing enlarged orange tonsils, hepatosplenomegaly, peripheral neuropathy, and accelerated atherosclerosis resulting from impaired reverse cholesterol transport. ABCA1 genetic variants associate with late-onset Alzheimer's disease risk, with altered ABCA1 function potentially influencing amyloid-β metabolism through effects on cellular cholesterol distribution and apoE lipidation status that modulate amyloid precursor protein processing and Aβ clearance. |
